| 1. Meyer MD, Hancock AA, Tietje K, Sippy KB, Prasad R, Stout DM, Arendsen DL, Donner BG, Carroll WA.. (1997) Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT uptake inhibiting and alpha2-antagonistic activities., 40 (7): [PMID:9089327] [10.1021/jm960723m] |
| 2. Lombardo F, Obach RS, Shalaeva MY, Gao F.. (2004) Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics., 47 (5): [PMID:14971904] [10.1021/jm030408h] |
| 3. Davies HM, Saikali E, Huby NJ, Gilliatt VJ, Matasi JJ, Sexton T, Childers SR.. (1994) Synthesis of 2 beta-acyl-3 beta-aryl-8-azabicyclo[3.2.1]octanes and their binding affinities at dopamine and serotonin transport sites in rat striatum and frontal cortex., 37 (9): [PMID:8176704] [10.1021/jm00035a005] |
| 4. Goodman MM, Kung MP, Kabalka GW, Kung HF, Switzer R.. (1994) Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents., 37 (10): [PMID:8182712] [10.1021/jm00036a020] |
| 5. Lee BS, Chu S, Lee BC, Chi DY, Choe YS, Jeong KJ, Jin C.. (2000) Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1., 10 (14): [PMID:10915050] [10.1016/s0960-894x(00)00290-0] |
| 6. Meyer MD, Hancock AA, Tietje K, Sippy kB, Giardina WJ, Kerwin JF. (1995) Synthesis and pharmacological characterization of A-80426: A putative novel antidepressant combining -2 antagonism with 5-HT uptake inhibition, 5 (19): [10.1016/0960-894X(95)00398-D] |
| 7. Keverline-Frantz KI, Boja JW, Kuhar MJ, Abraham P, Burgess JP, Lewin AH, Carroll FI.. (1998) Synthesis and ligand binding of tropane ring analogues of paroxetine., 41 (2): [PMID:9457247] [10.1021/jm970669p] |
| 8. Yoshida F, Topliss JG.. (2000) QSAR model for drug human oral bioavailability., 43 (13): [PMID:10891117] [10.1021/jm0000564] |
| 9. Maryanoff BE, Vaught JL, Shank RP, McComsey DF, Costanzo MJ, Nortey SO.. (1990) Pyrroloisoquinoline antidepressants. 3. A focus on serotonin., 33 (10): [PMID:2213832] [10.1021/jm00172a018] |
| 10. Wei P, Kaatz GW, Kerns RJ.. (2004) Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps., 14 (12): [PMID:15149651] [10.1016/j.bmcl.2004.04.018] |
| 11. Martínez-Esparza J, Oficialdegui AM, Pérez-Silanes S, Heras B, Orús L, Palop JA, Lasheras B, Roca J, Mourelle M, Bosch A, Del Castillo JC, Tordera R, Del Río J, Monge A.. (2001) New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants., 44 (3): [PMID:11462981] [10.1021/jm001059j] |
| 12. Carlier PR, Lo MM, Lo PC, Richelson E, Tatsumi M, Reynolds IJ, Sharma TA.. (1998) Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group., 8 (5): [PMID:9871604] [10.1016/s0960-894x(98)00062-6] |
| 13. Orjales A, Mosquera R, Toledo A, Pumar MC, García N, Cortizo L, Labeaga L, Innerárity A.. (2003) Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters., 46 (25): [PMID:14640559] [10.1021/jm0309349] |
| 14. Se Lee B, Chu S, Lee BS, Yoon Chi D, Song YS, Jin C.. (2002) Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines., 12 (5): [PMID:11859009] [10.1016/s0960-894x(02)00028-8] |
| 15. Mattson RJ, Catt JD, Denhart DJ, Deskus JA, Ditta JL, Higgins MA, Marcin LR, Sloan CP, Beno BR, Gao Q, Cunningham MA, Mattson GK, Molski TF, Taber MT, Lodge NJ.. (2005) Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors., 48 (19): [PMID:16162005] [10.1021/jm0503291] |
| 16. Wan H, Rehngren M, Giordanetto F, Bergström F, Tunek A.. (2007) High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery., 50 (19): [PMID:17725338] [10.1021/jm070375w] |
| 17. Gelmi ML, Caputo F, Clerici F, Pellegrino S, Giannaccini G, Betti L, Fabbrini L, Schmid L, Palego L, Lucacchini A.. (2007) 1-Aminocyclopentane-1,2,4-tricarboxylic acids screening on glutamatergic and serotonergic systems., 15 (24): [PMID:17900912] [10.1016/j.bmc.2007.09.004] |
| 18. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E.. (2008) Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model., 51 (2): [PMID:18027916] [10.1021/jm070524a] |
| 19. German N, Kaatz GW, Kerns RJ.. (2008) Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps., 18 (4): [PMID:18242086] [10.1016/j.bmcl.2008.01.014] |
| 20. Petrascheck M, Ye X, Buck LB.. (2007) An antidepressant that extends lifespan in adult Caenorhabditis elegans., 450 (7169): [PMID:18033297] [10.1038/nature05991] |
| 21. Wan H, Ahman M, Holmén AG.. (2009) Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs., 52 (6): [PMID:19256501] [10.1021/jm801441s] |
| 22. Funke U, Fischer S, Hiller A, Scheunemann M, Deuther-Conrad W, Brust P, Steinbach J.. (2008) 3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination., 18 (16): [PMID:18644726] [10.1016/j.bmcl.2008.06.077] |
| 23. McComas CC, Vu AT, Mahaney PE, Cohn ST, Fensome A, Marella MA, Nogle L, Trybulski EJ, Ye F, Zhang P, Alfinito P, Bray J, Johnston G, Koury E, Deecher DC.. (2008) Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors., 18 (18): [PMID:18771916] [10.1016/j.bmcl.2008.08.060] |
| 24. van der Lee MJ, Blenke AA, Rongen GA, Verwey-van Wissen CP, Koopmans PP, Pharo C, Burger DM.. (2007) Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects., 51 (11): [PMID:17846135] [10.1128/aac.01243-06] |
| 25. Ben-Daniel R, Deuther-Conrad W, Scheunemann M, Steinbach J, Brust P, Mishani E.. (2008) Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter., 16 (12): [PMID:18487050] [10.1016/j.bmc.2008.05.006] |
| 26. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.. (2009) Physicochemical determinants of human renal clearance., 52 (15): [PMID:19445515] [10.1021/jm900403j] |
| 27. Langham JJ, Cleves AE, Spitzer R, Kirshner D, Jain AN.. (2009) Physical binding pocket induction for affinity prediction., 52 (19): [PMID:19754201] [10.1021/jm901096y] |
| 28. Prado-Prado FJ, García-Mera X, González-Díaz H.. (2010) Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species., 18 (6): [PMID:20185316] [10.1016/j.bmc.2010.01.068] |
| 29. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.. (2006) Identifying off-target effects and hidden phenotypes of drugs in human cells., 2 (6): [PMID:16680159] [10.1038/nchembio790] |
| 30. Alelyunas YW, Empfield JR, McCarthy D, Spreen RC, Bui K, Pelosi-Kilby L, Shen C.. (2010) Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate., 20 (24): [PMID:21055935] [10.1016/j.bmcl.2010.10.068] |
| 31. PubChem BioAssay data set, |
| 32. PubChem BioAssay data set, |
| 33. Obach RS, Lombardo F, Waters NJ.. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds., 36 (7): [PMID:18426954] [10.1124/dmd.108.020479] |
| 34. Brincat JP, Carosati E, Sabatini S, Manfroni G, Fravolini A, Raygada JL, Patel D, Kaatz GW, Cruciani G.. (2011) Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus., 54 (1): [PMID:21141825] [10.1021/jm1011963] |
| 35. Nencetti S, Mazzoni MR, Ortore G, Lapucci A, Giuntini J, Orlandini E, Banti I, Nuti E, Lucacchini A, Giannaccini G, Rossello A.. (2011) Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors., 46 (3): [PMID:21272963] [10.1016/j.ejmech.2010.12.018] |
| 36. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.. (2010) Developing structure-activity relationships for the prediction of hepatotoxicity., 23 (7): [PMID:20553011] [10.1021/tx1000865] |
| 37. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 38. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 39. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.. (2004) Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling., 1 (4): [PMID:16472241] [10.2174/1570163043334794] |
| 40. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 41. Fontana E, Dansette PM, Poli SM.. (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity., 6 (1): [PMID:16248836] [10.2174/138920005774330639] |
| 42. Sabatini S, Gosetto F, Manfroni G, Tabarrini O, Kaatz GW, Patel D, Cecchetti V.. (2011) Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump., 54 (16): [PMID:21751791] [10.1021/jm200370y] |
| 43. Seo HJ, Park EJ, Kim MJ, Kang SY, Lee SH, Kim HJ, Lee KN, Jung ME, Lee M, Kim MS, Son EJ, Park WK, Kim J, Lee J.. (2011) Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter., 54 (18): [PMID:21823597] [10.1021/jm200682b] |
| 44. PubChem BioAssay data set, |
| 45. PubChem BioAssay data set, |
| 46. PubChem BioAssay data set, |
| 47. PubChem BioAssay data set, |
| 48. PubChem BioAssay data set, |
| 49. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 50. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.. (2011) FDA-approved drug labeling for the study of drug-induced liver injury., 16 (15-16): [PMID:21624500] [10.1016/j.drudis.2011.05.007] |
| 51. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 52. Sabatini S, Gosetto F, Serritella S, Manfroni G, Tabarrini O, Iraci N, Brincat JP, Carosati E, Villarini M, Kaatz GW, Cecchetti V.. (2012) Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors., 55 (7): [PMID:22432682] [10.1021/jm201446h] |
| 53. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.. (2012) Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., 25 (10): [PMID:22931300] [10.1021/tx300075j] |
| 54. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE.. (2003) Inhibition of P-glycoprotein by newer antidepressants., 305 (1): [PMID:12649369] [10.1124/jpet.102.046532] |
| 55. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 56. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.. (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions., 55 (10): [PMID:22541068] [10.1021/jm300212s] |
| 57. Hernandez-Olmos V, Abdelrahman A, El-Tayeb A, Freudendahl D, Weinhausen S, Müller CE.. (2012) N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists., 55 (22): [PMID:23075067] [10.1021/jm300845v] |
| 58. Bartusik D, Tomanek B, Blicharska B, Fallone G. (2011) Magnetic resonance assays of haloperidol in human serum albumin, 20 (1): [10.1007/s00044-009-9287-4] |
| 59. Noorizadeh H, Noorizadeh M, Farmany A. (2012) Advanced QSRR models of toxicological screening of basic drugs in whole blood by UPLC-TOFMS, 21 (12): [10.1007/s00044-012-9977-1] |
| 60. PubChem BioAssay data set, |
| 61. Wu YJ, He H, Bertekap R, Westphal R, Lelas S, Newton A, Wallace T, Taber M, Davis C, Macor JE, Bronson J.. (2013) Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression., 21 (8): [PMID:23477943] [10.1016/j.bmc.2013.02.010] |
| 62. Sabatini S, Gosetto F, Iraci N, Barreca ML, Massari S, Sancineto L, Manfroni G, Tabarrini O, Dimovska M, Kaatz GW, Cecchetti V.. (2013) Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance., 56 (12): [PMID:23710549] [10.1021/jm400262a] |
| 63. Unpublished dataset, |
| 64. Settimo L, Bellman K, Knegtel RM.. (2013) Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds., [PMID:24249037] [10.1007/s11095-013-1232-z] |
| 65. Tian M, Abdelrahman A, Weinhausen S, Hinz S, Weyer S, Dosa S, El-Tayeb A, Müller CE.. (2014) Carbamazepine derivatives with P2X4 receptor-blocking activity., 22 (3): [PMID:24411477] [10.1016/j.bmc.2013.12.035] |
| 66. Stepan AF, Mascitti V, Beaumont K, Kalgutkar AS. (2013) Metabolism-guided drug design, 4 (4): [10.1039/C2MD20317K] |
| 67. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 68. PubChem BioAssay data set, |
| 69. Pieroni M, Sabatini S, Massari S, Kaatz GW, Cecchetti V, Tabarrini O. (2012) Searching for innovative quinolone-like scaffolds: synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives, 3 (9): [10.1039/C2MD20101A] |
| 70. Mateus A, Matsson P, Artursson P.. (2014) A high-throughput cell-based method to predict the unbound drug fraction in the brain., 57 (7): [PMID:24601604] [10.1021/jm401963n] |
| 71. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 72. Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning, [10.6019/CHEMBL3392926] |
| 73. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM.. (2013) MICE models: superior to the HERG model in predicting Torsade de Pointes., 3 [PMID:23812503] [10.1038/srep02100] |
| 74. Longhi R, Corbioli S, Fontana S, Vinco F, Braggio S, Helmdach L, Schiller J, Boriss H.. (2011) Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method., 39 (2): [PMID:21071520] [10.1124/dmd.110.036095] |
| 75. Loi CM, Smith DA, Dalvie D.. (2013) Which metabolites circulate?, 41 (5): [PMID:23454828] [10.1124/dmd.112.050278] |
| 76. Curran RE, Claxton CR, Hutchison L, Harradine PJ, Martin IJ, Littlewood P.. (2011) Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding., 39 (3): [PMID:21098647] [10.1124/dmd.110.036988] |
| 77. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE.. (2011) Species independence in brain tissue binding using brain homogenates., 39 (7): [PMID:21474681] [10.1124/dmd.111.038778] |
| 78. Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, Parkinson A.. (2013) Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)., 41 (4): [PMID:23378628] [10.1124/dmd.112.050054] |
| 79. Drug metabolism data, |
| 80. Joshi P, Singh S, Wani A, Sharma S, Jain SK, Singh B, Gupta BD, Satti NK, Koul S, Khan IA, Kumar A, Bharate SB, Vishwakarma RA. (2014) Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: reversing the resistance against frontline antibacterial drugs, 5 (10): [10.1039/C4MD00196F] |
| 81. Waldschmidt HV, Homan KT, Cruz-Rodríguez O, Cato MC, Waninger-Saroni J, Larimore KM, Cannavo A, Song J, Cheung JY, Kirchhoff PD, Koch WJ, Tesmer JJ, Larsen SD.. (2016) Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors., 59 (8): [PMID:27050625] [10.1021/acs.jmedchem.5b02000] |
| 82. Neves BJ, Dantas RF, Senger MR, Valente WCG, Rezende-Neto JdM, Chaves WT, Kamentsky L, Carpenter A, Silva-Junior FP, Andrade CH. (2016) The antidepressant drug paroxetine as a new lead candidate in schistosome drug discovery, 7 (6): [10.1039/C5MD00596E] |
| 83. WHO Anatomical Therapeutic Chemical Classification, |
| 84. Yoshinaga H, Masumoto S, Koyama K, Kinomura N, Matsumoto Y, Kato T, Baba S, Matsumoto K, Horisawa T, Oki H, Yabuuchi K, Kodo T.. (2017) Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT1A weak partial agonistic activity showing the antidepressant-like effect., 25 (1): [PMID:27865645] [10.1016/j.bmc.2016.10.034] |
| 85. DrugMatrix, [10.6019/CHEMBL3885881] |
| 86. Soubhye J, Chikh Alard I, Aldib I, Prévost M, Gelbcke M, De Carvalho A, Furtmüller PG, Obinger C, Flemmig J, Tadrent S, Meyer F, Rousseau A, Nève J, Mathieu V, Zouaoui Boudjeltia K, Dufrasne F, Van Antwerpen P.. (2017) Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure., 60 (15): [PMID:28671460] [10.1021/acs.jmedchem.7b00285] |
| 87. Yang X, Goswami S, Gorityala BK, Domalaon R, Lyu Y, Kumar A, Zhanel GG, Schweizer F.. (2017) A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria., 60 (9): [PMID:28399372] [10.1021/acs.jmedchem.7b00156] |
| 88. Ren J, Zhao Y, Fry EE, Stuart DI.. (2018) Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection., 61 (3): [PMID:29272110] [10.1021/acs.jmedchem.7b01249] |
| 89. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 90. Waldschmidt HV, Homan KT, Cato MC, Cruz-Rodríguez O, Cannavo A, Wilson MW, Song J, Cheung JY, Koch WJ, Tesmer JJ, Larsen SD.. (2017) Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine., 60 (7): [PMID:28323425] [10.1021/acs.jmedchem.7b00112] |
| 91. Unpublished dataset, |
| 92. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 93. Werner S, Mesch S, Hillig RC, Ter Laak A, Klint J, Neagoe I, Laux-Biehlmann A, Dahllöf H, Bräuer N, Puetter V, Nubbemeyer R, Schulz S, Bairlein M, Zollner TM, Steinmeyer A.. (2019) Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile., 62 (24): [PMID:31746599] [10.1021/acs.jmedchem.9b01304] |
| 94. Rana P, Will Y, Nadanaciva S, Jones LH.. (2016) Development of a cell viability assay to assess drug metabolite structure-toxicity relationships., 26 (16): [PMID:27397500] [10.1016/j.bmcl.2016.06.088] |
| 95. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 96. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 97. Matsunaga N, Nunoya K, Okada M, Ogawa M, Tamai I.. (2013) Evaluation of hepatic disposition of paroxetine using sandwich-cultured rat and human hepatocytes., 41 (4): [PMID:23303441] [10.1124/dmd.112.049817] |
| 98. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 99. Xu G,Gaul MD,Liu Z,DesJarlais RL,Qi J,Wang W,Krosky D,Petrounia I,Milligan CM,Hermans A,Lu HR,Huang DZ,Xu JZ,Spurlino JC. (2020) Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor., 30 (23): [PMID:33038544] [10.1016/j.bmcl.2020.127602] |
| 100. Rowlands RA,Chen Q,Bouley RA,Avramova LV,Tesmer JJG,White AD. (2021) Generation of Highly Selective, Potent, and Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors., 64 (1.0): [PMID:33393767] [10.1021/acs.jmedchem.0c01522] |
| 101. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 102. Staroń J, Pietruś W, Bugno R, Kurczab R, Satała G, Warszycki D, Lenda T, Wantuch A, Hogendorf AS, Hogendorf A, Duszyńska B, Bojarski AJ.. (2021) Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine., 220 [PMID:34049262] [10.1016/j.ejmech.2021.113533] |
| 103. Morales-Tenorio M, Ginex T, Cuesta-Geijo MÁ, Campillo NE, Muñoz-Fontela C, Alonso C, Delgado R, Gil C.. (2021) Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction., 223 [PMID:34175537] [10.1016/j.ejmech.2021.113654] |
| 104. Han S, Li H, Chen W, Yang L, Tong X, Zuo J, Hu Y.. (2022) Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold., 240 [PMID:35872393] [10.1016/j.ejmech.2022.114608] |
| 105. Zhou CG, Xiang ZN, Zhao N, Sun X, Hu ZF, Wu JL, Xia RF, Chen C, Su JC, Chen JC, Wan LS.. (2022) Jatrophane Diterpenoids with Kv1.3 Ion Channel Inhibitory Effects from Euphorbia helioscopia., 85 (4.0): [PMID:35245067] [10.1021/acs.jnatprod.1c00879] |
| 106. Xie Z, Yang X, Duan Y, Han J, Liao C.. (2021) Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases., 64 (3.0): [PMID:33481605] [10.1021/acs.jmedchem.0c01511] |
| 107. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
